Literature DB >> 12897096

Relationship of non-LDL-bound apo(a), urinary apo(a) fragments and plasma Lp(a) in patients with impaired renal function.

Edmund Cauza1, Josef Kletzmaier, Gert Bodlaj, Attila Dunky, Wolfgang Herrmann, Karam Kostner.   

Abstract

BACKGROUND: Plasma lipoprotein (a) [Lp(a)] has been shown to be a risk factor for atherosclerosis in numerous studies. However, the catabolism of this lipoprotein is not very clear. We and others have shown that Lp(a) is excreted into urine in the form of fragments. Lp(a) has also been shown to exist in a low-density non-lipoprotein (LDL)-bound form. Since Lp(a) is increased in all forms of kidney disease with reduced excretory kidney function and decreased excretion of apo(a) fragments could be partially responsible for this increase, we investigated the relationship of non-LDL-bound apo(a), urinary apo(a) fragments and plasma Lp(a) in patients with impaired renal function.
METHODS: Plasma Lp(a), non-LDL-bound apo(a) and urinary apo(a) fragments were measured in 55 kidney disease patients (28 males and 27 females) and matched controls.
RESULTS: Plasma Lp(a) and non-LDL-bound apo(a) were increased in patients, whereas urinary apo(a) was decreased, especially in patients with a creatinine clearance < 70 ml/min. There was a significant correlation between plasma Lp(a) and non-LDL-bound apo(a) in patients and controls.
CONCLUSION: We conclude that decreased urinary apo(a) excretion could be one possible mechanism of increased plasma Lp(a) and non-LDL-bound apo(a) in patients with decreased kidney function.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12897096     DOI: 10.1093/ndt/gfg181

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  5 in total

1.  Lipoprotein(a) Particle Production as a Determinant of Plasma Lipoprotein(a) Concentration Across Varying Apolipoprotein(a) Isoform Sizes and Background Cholesterol-Lowering Therapy.

Authors:  Dick C Chan; Gerald F Watts; Blai Coll; Scott M Wasserman; Santica M Marcovina; P Hugh R Barrett
Journal:  J Am Heart Assoc       Date:  2019-04-02       Impact factor: 5.501

Review 2.  The metabolism of lipoprotein (a): an ever-evolving story.

Authors:  Gissette Reyes-Soffer; Henry N Ginsberg; Rajasekhar Ramakrishnan
Journal:  J Lipid Res       Date:  2017-07-18       Impact factor: 5.922

3.  Suboptimal medical care of patients with ST-elevation myocardial infarction and renal insufficiency: results from the Korea Acute Myocardial Infarction Registry.

Authors:  Joon Seok Choi; Chang Seong Kim; Eun Hui Bae; Seong Kwon Ma; Myung Ho Jeong; Young Jo Kim; Myeong Chan Cho; Chong Jin Kim; Soo Wan Kim
Journal:  BMC Nephrol       Date:  2012-09-11       Impact factor: 2.388

4.  Effect of Nandrolone Decanoate on serum lipoprotein (a) and its isoforms in hemodialysis patients.

Authors:  Amir Ghorbanihaghjo; Hassan Argani; Mohammad Rohbaninoubar; Nadereh Rashtchizadeh
Journal:  Lipids Health Dis       Date:  2004-06-29       Impact factor: 3.876

Review 5.  The role of lipoprotein (a) in chronic kidney disease.

Authors:  Jemma C Hopewell; Richard Haynes; Colin Baigent
Journal:  J Lipid Res       Date:  2018-01-29       Impact factor: 5.922

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.